Join Growin Stock Community!

Fortress biotech, inc.FBIO.US Overview

US StockHealthcare
(No presentation for FBIO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

FBIO AI Insights

FBIO Overall Performance

FBIO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

FBIO Recent Performance

-2.49%

Fortress biotech, inc.

0.05%

Avg of Sector

-0.31%

S&P500

FBIO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

FBIO Key Information

FBIO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

FBIO Profile

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

Price of FBIO

FBIO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

FBIO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.70
PB Ratio
1.91
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
71.56%
Net Margin
6.40%
Revenue Growth (YoY)
-0.32%
Profit Growth (YoY)
17.80%
3-Year Revenue Growth
2.18%
3-Year Profit Growth
8.46%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.70
PB Ratio
1.91
Price-to-FCF
-
Gross Margin
71.56%
Net Margin
6.40%
Revenue Growth (YoY)
-0.32%
Profit Growth (YoY)
17.80%
3-Year Revenue Growth
2.18%
3-Year Profit Growth
8.46%

  • When is FBIO's latest earnings report released?

    The most recent financial report for Fortress biotech, inc. (FBIO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating FBIO's short-term business performance and financial health. For the latest updates on FBIO's earnings releases, visit this page regularly.

  • Where does FBIO fall in the P/E River chart?

    According to historical valuation range analysis, Fortress biotech, inc. (FBIO)'s current price-to-earnings (P/E) ratio is -15.24, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of FBIO?

    According to the latest financial report, Fortress biotech, inc. (FBIO) reported an Operating Profit of -6.81M with an Operating Margin of -38.63% this period, representing a growth of 69.17% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is FBIO's revenue growth?

    In the latest financial report, Fortress biotech, inc. (FBIO) announced revenue of 17.63M, with a Year-Over-Year growth rate of 20.52%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does FBIO have?

    As of the end of the reporting period, Fortress biotech, inc. (FBIO) had total debt of 68.29M, with a debt ratio of 0.38. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does FBIO have?

    At the end of the period, Fortress biotech, inc. (FBIO) held Total Cash and Cash Equivalents of 87.44M, accounting for 0.48 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does FBIO go with three margins increasing?

    In the latest report, Fortress biotech, inc. (FBIO) did not achieve the “three margins increasing” benchmark, with a gross margin of 67.4%%, operating margin of -38.63%%, and net margin of 20.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess FBIO's profit trajectory and future growth potential.

  • Is FBIO's EPS continuing to grow?

    According to the past four quarterly reports, Fortress biotech, inc. (FBIO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.13. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of FBIO?

    Fortress biotech, inc. (FBIO)'s Free Cash Flow (FCF) for the period is -6.11M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 69.54% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of FBIO?

    The latest valuation data shows Fortress biotech, inc. (FBIO) has a Price-To-Earnings (PE) ratio of -15.24 and a Price/Earnings-To-Growth (PEG) ratio of -0.04. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.